These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 18323826)

  • 1. Despite potential side effects, two drugs make a comeback.
    Bjorn G
    Nat Med; 2008 Mar; 14(3):226. PubMed ID: 18323826
    [No Abstract]   [Full Text] [Related]  

  • 2. Similar neurotoxicity of an alternating compared to a continuous low-dose schedule of thalidomide for relapsed/refractory multiple myeloma.
    Mangiacavalli S; Albani G; Caravita T; Cocito F; Pascutto C; Zappasodi P; Bringhen S; Palumbo A; Cazzola M; Corso A
    Leuk Lymphoma; 2012 Mar; 53(3):514-5. PubMed ID: 22141736
    [No Abstract]   [Full Text] [Related]  

  • 3. Lenalidomide-induced cytokine release syndrome in a patient with multiple myeloma.
    Nakamura N; Kanemura N; Shibata Y; Matsumoto T; Mabuchi R; Nakamura H; Kitagawa J; Goto N; Hara T; Tsurumi H; Moriwaki H
    Leuk Lymphoma; 2014 Jul; 55(7):1691-3. PubMed ID: 24138307
    [No Abstract]   [Full Text] [Related]  

  • 4. Lenalidomide and its role in the management of multiple myeloma.
    Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A
    Expert Rev Anticancer Ther; 2008 Jun; 8(6):865-74. PubMed ID: 18533796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel therapies in monoclonal gammopathies.
    Niesvizky R
    Hematology; 2012 Apr; 17 Suppl 1():S121-4. PubMed ID: 22507798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lenalidomide, a thalidomide derivative, shows promise in various applications.
    Oestreicher P
    ONS Connect; 2007 Aug; 22(8):22-3. PubMed ID: 17824579
    [No Abstract]   [Full Text] [Related]  

  • 7. The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents.
    Gavriatopoulou M; Kastritis E; Ntanasis-Stathopoulos I; Fotiou D; Roussou M; Migkou M; Ziogas DC; Kanellias N; Terpos E; Dimopoulos MA
    Blood; 2018 Jan; 131(4):464-467. PubMed ID: 29167176
    [No Abstract]   [Full Text] [Related]  

  • 8. A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings.
    Stadtmauer EA; Lonial S; Vesole DH; Abonour R; Alsina M; Badros A; Comenzo R; Durie B; Giralt S; Hussein M; Jakubowiak A; Mehta J; Niesvizky R; Orlowski R; Siegel D; Singhal S; Vescio R; Wang M; Zangari M; Munshi NC
    Clin Adv Hematol Oncol; 2007 Oct; 5(10 Suppl 15):7-19, quiz 21-2. PubMed ID: 18000495
    [No Abstract]   [Full Text] [Related]  

  • 9. [Treatment of multiple myeloma with thalidomide and immunomodulatory drugs].
    Hattori Y
    Nihon Rinsho; 2007 Jan; 65 Suppl 1():596-600. PubMed ID: 17476758
    [No Abstract]   [Full Text] [Related]  

  • 10. Multiple myeloma patient care: treatment options and nursing considerations.
    McGee L
    ONS Connect; 2007; 22(8 Suppl):67-8. PubMed ID: 17824572
    [No Abstract]   [Full Text] [Related]  

  • 11. Lenalidomide--the phoenix rises.
    List AF
    N Engl J Med; 2007 Nov; 357(21):2183-6. PubMed ID: 18032768
    [No Abstract]   [Full Text] [Related]  

  • 12. Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer.
    Bennett CL; Angelotta C; Yarnold PR; Evens AM; Zonder JA; Raisch DW; Richardson P
    JAMA; 2006 Dec; 296(21):2558-60. PubMed ID: 17148721
    [No Abstract]   [Full Text] [Related]  

  • 13. Role of thalidomide in previously untreated patients with multiple myeloma.
    Musto P; D'Auria F; Pietrantuono G; Bringhen S; Morabito F; Di Raimondo F; Pozzi S; Sacchi S; Boccadoro M; Palumbo A; ;
    Expert Rev Anticancer Ther; 2008 Oct; 8(10):1569-80. PubMed ID: 18925849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Side effects and good effects from new chemotherapeutic agents. Case 2. Thalidomide-induced interstitial pneumonitis.
    Onozawa M; Hashino S; Sogabe S; Haneda M; Horimoto H; Izumiyama K; Kondo T; Aldana LP; Hamada K; Asaka M
    J Clin Oncol; 2005 Apr; 23(10):2425-6. PubMed ID: 15800335
    [No Abstract]   [Full Text] [Related]  

  • 15. [An old drug as a carcinostatic. The new career of thalidomide].
    Holzgrabe U
    Pharm Unserer Zeit; 2007; 36(6):446-9. PubMed ID: 17957689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Classical hodgkin lymphoma as de novo B-cell malignancy after treatment of multiple myeloma in the pre-lenalidomide era.
    Zago M; Adam P; Goldschmidt H; Fend F; Kanz L; Weisel K
    Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):e7-e11. PubMed ID: 24169269
    [No Abstract]   [Full Text] [Related]  

  • 17. Reducing neurotoxicity in the management of multiple myeloma.
    Gertz MA
    Leuk Lymphoma; 2011 Nov; 52(11):2043-4. PubMed ID: 21740295
    [No Abstract]   [Full Text] [Related]  

  • 18. Complete regression of HIV-associated multicentric Castleman disease treated with rituximab and thalidomide.
    Stary G; Kohrgruber N; Herneth AM; Gaiger A; Stingl G; Rieger A
    AIDS; 2008 Jun; 22(10):1232-4. PubMed ID: 18525273
    [No Abstract]   [Full Text] [Related]  

  • 19. Tumor lysis syndrome at the beginning of thalidomide therapy for multiple myeloma.
    Cany L; Fitoussi O; Boiron JM; Marit G
    J Clin Oncol; 2002 Apr; 20(8):2212. PubMed ID: 11956286
    [No Abstract]   [Full Text] [Related]  

  • 20. [Treatment of multiple myeloma by immunomodulatory drugs].
    Hata H
    Rinsho Ketsueki; 2011 Oct; 52(10):1485-95. PubMed ID: 21971225
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.